CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 278 enrolled
Drug / intervention
Combination therapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03597841
NCT03597841N/ACompleted
CompareCT.gov

Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia: a National Multicenter Observational Study

Koç University·observational·Posted Jul 24, 2018·Updated Jul 24, 2019

In Brief

An observational study evaluating Combination therapy for Klebsiella Pneumonia and Bacteremia. Completed, enrolled 278 participants across 15 sites.

Detailed Summary

Carbapenem-resistant Klebsiella pneumonia (CRKp) blood stream infections (BSI) cause substantial mortality among hospitalized patients. Treatment options for CRKp infections are limited and increasing resistance rates to few available drugs, i.e., colistin, is a big concern. This prospective multicenter observational study is designed to describe clinical characteristics and outcomes of patients with CRKp bacteremia in an oxacillinase-48 (OXA-48) endemic country to define predictors of mortality with a focus on the impact of mono versus combination therapies on mortality. The study will also investigate risk factors associated with colistin-resistant CRKp BSI.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKlebsiella Pneumonia, Bacteremia
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 24, 2018
Enrollment StartJun 25, 2018
Primary CompletionJun 25, 2019
Study CompletionJul 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 7.9 years ago

Interventions

Combination therapydrug

Patients who are given combination therapy will be allocated to this group.